· Published by Health Canada · Official notice
This is duplicated text of a letter from Merck Canada Inc. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
March 28, 2014
Subject: Association of REMERON® / REMERON RD® (mirtazapine) and abnormal heart rhythm
Merck Canada Inc., in consultation with Health Canada, would like to inform you of important safety information about REMERON® / REMERON RD® (mirtazapine) and abnormal heart rhythm. REMERON® / REMERON RD® is a medication given for depression.
Patients with these abnormal heart rhythms may feel dizzy, faint or have seizures. It may cause death if not treated.
REMERON® / REMERON RD® product information may be obtained on the Merck Canada website or on the Health Canada website.
Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing side effects are generally presumed to underestimate the risks associated with health product treatments. Any case of serious QT Prolongation/torsades de pointes or other serious or unexpected side effects in patients receiving REMERON®/REMERON RD® should be reported to Merck Canada Inc. or Health Canada.
Merck Canada Inc., Pharmacovigilance
16750 Trans-Canada Hwy.
Kirkland, Québec H9H 4M7
Fax: 1-800-369-3090
You can report any suspected side effect associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Mauricio Ede, M.D./
Executive Director, Medical Affairs
®Registered trademark of Merck Sharp & Dohme B.V. Used under license.